CRMY Technologies Sdn Bhd (CTSB) is the commercial arm of Cancer Research Malaysia (CRMY), established to translate research discoveries into scalable solutions that improve cancer prevention, diagnosis, and treatment.
Through intellectual property stewardship, commercialisation strategies, and implementation of technologies such as Genetix and MeMoSA®, CTSB enables CRMY’s research innovations to reach healthcare providers, partners, and communities beyond the laboratory.
Integrated genetic counselling and clinical testing tailored for high-risk families and precision prevention.
AI-powered mobile app for early oral cancer detection, bringing specialist-supported screening to remote communities.
AI-powered mobile app for early oral cancer detection, bringing specialist-supported screening to remote communities.
Malaysia’s first DNA cancer vaccine advancing next-generation cancer immunotherapy.
Years of Groundbreaking Cancer Research
Patients Genetically Tested & Counselled
Screened for Early Oral Cancer Detection
Malaysian-Developed Cancer Vaccine Candidate
Years of Groundbreaking
Cancer Research
Patients Genetically Tested
& Counselled
Screened for Early Oral
Cancer Detection
Malaysian-Developed
Cancer Vaccine Candidate
CRMY Technologies Sdn. Bhd.
202101031165 (1431465H)
+60 12-264 3894 (WhatsApp only)
Level 1, Subang Jaya Medical Centre
South Tower, Selangor, Malaysia
